TBPH β€” THERAVANCE BIOPHARMA INC

Ownership history in EntryPoint Capital, LLC  Β·  3 quarters on record

This page tracks every 13F SEC filing in which EntryPoint Capital, LLC reported a position in THERAVANCE BIOPHARMA INC (TBPH). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.25% (2025 Q4)
πŸ“Š Avg. % of fund
0.19%
πŸ“… First filed
2025 Q2
πŸ“… Last filed
2025 Q4
⏱ Quarters held
3

Position Intelligence

EntryPoint Capital, LLC Γ— TBPH AI Analytics

πŸ“ˆ EntryPoint Capital, LLC outperformed the S&P 500 by +99.5% annually on this TBPH position. Average cost basis: $12.23. Maximum drawdown during holding period: –0.0%.

πŸ“ˆ Position Alpha vs SPY
+99.5%
annualised excess return

πŸ”₯ Exceptional β€” beat the S&P 500 by 99.5% per year on this position.
2 quarters analyzed

πŸ’° Entry Quality
$12.23
+53.0% vs current ($18.71)

Best entry: $11.03 (2025 Q2)  Β·  Worst: $18.71 (2025 Q4)

πŸ›‘οΈ Drawdown Resilience
–0.0%
max drawdown while held

πŸ’Ž No drawdown exceeding 20% during the holding period β€” exceptionally stable.

πŸ’ͺ Fund Conviction
100%
buy-side decisions

3 adds Β· 0 trims. πŸ‚ Consistently bullish β€” fund kept accumulating this position.

πŸ“‘ Position Trajectory
β†’ Stable
last 4–5 quarters trend

βš–οΈ Portfolio weight has remained relatively stable β€” conviction maintained.
Currently 0.25% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    TBPH price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 3 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 ADDED 34,575 +4,320 +14.3% 0.25% $647K $18.71
2025 Q3 ADDED 30,255 +2,351 +8.4% 0.17% $442K $14.60
2025 Q2 INITIATED 27,904 β€” β€” 0.15% $308K $11.03
← Back to EntryPoint Capital, LLC Holdings